-

ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML
From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world’s top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr.…
-

Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients
Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China’s aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao…
-

CUA 2024丨Dr. Jian Huang Shares Key Areas of Focus at the CUA Annual Meeting and Sun Yat-sen Memorial Hospital ’s Bladder Cancer Research
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19 to 22, 2024, at the National Convention Center in Tianjin. This event brought together leading urology experts from China and abroad to discuss the latest advances in clinical research and surgical treatment. After…
-

Dr. Qiang Wei: Precision Endocrine Therapy for Prostate Cancer Enters a New Era as the West China Hospital Continues to Pioneer Diagnostic
Prostate cancer is one of the most common malignancies in men, with endocrine therapy being a standard treatment approach. However, it often comes with some side effects. Recently, the 31st Annual Urology Conference, hosted by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19-22, 2024, at the Tianjin National…
-

CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University
From September 25-29, 2024, the “27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting,” hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed “Patient-Centered, Sharing the Future,” brings together the latest research advancements and developments in the field,…
-

CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and CSCO Academic Annual Meeting was successfully held in Xiamen. With the theme “Patient-Centered, Sharing the Future,” the conference gathered significant research progress and developments from both domestic and international fields. Dr. Sanjun Cai from Fudan University Shanghai Cancer Center chaired the…
-

CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer
From September 25 to 29, 2024, the much-anticipated 27th Annual Chinese Society of Clinical Oncology (CSCO) conference was held successfully in Xiamen. This prominent event gathered top experts from China’s oncology community, focusing on standardized pathways and cutting-edge advancements in the diagnosis and treatment of malignant tumors.During the conference, Dr. Gong Chen from the Sun…
-

CSCO 2024 | Dr. Jun Guo: “Two Decades of CSCO’s Glory and the New Chapter in Melanoma Diagnosis and Treatment”
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, is about to open in Xiamen. This grand event will bring together top domestic and international experts to share the latest research results and practical experiences. Ahead…